Actively Recruiting
Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA).
Led by Samuel Fortin · Updated on 2025-12-11
48
Participants Needed
2
Research Sites
138 weeks
Total Duration
On this page
Sponsors
S
Samuel Fortin
Lead Sponsor
I
Institut de recherche clinique du littoral (IRCL)
Collaborating Sponsor
AI-Summary
What this Trial Is About
A growing body of studies shows that omega-3s act directly in molecular signaling pathways that reduce inflammation and are thought to have a positive effect on cognitive health. Brain fog is a term that has been popularized in the medical world in the wake of the COVID-19 pandemic. A significant proportion of patients with long COVID reported having cognitive sequelae that were like fogginess. It is defined as a cognitive impairment with characteristic symptoms including problems with concentration, attention and memory, confusion, difficulty understanding what others are saying, reduced mental acuity and mental fatigue. These are episodes of reduced cognitive capacity that are not representative of the person's normal state. This condition can be caused by various factors such as stress, lack of sleep, overwork, depression, hormonal changes due to pregnancy or menopause in women, head injuries, migraine, certain diseases or viral infections, certain medications as well as substance abuse (alcohol and/or street drugs). In this study, we want to test whether omega-3 monoglycerides (MAG-EPA) can modulate the cognitive health of people with brain fog.
CONDITIONS
Official Title
Modulation of the Brain Fog Scale by Eicosapentaenoic Acid Monoglycerides (MAG-EPA).
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participant between 19 and 55 years of age.
- Reports having mental fatigue and/or frequent memory loss and/or difficulty concentrating and/or inattention, confusion and/or decreased cognitive acuity for at least 28 days.
- Obtains a mean score on Brain Fog Scale screening questionnaires of at least 30 or minimum scores on specific factors as defined.
- Available for the entire study duration and willing to participate with informed consent.
- No intellectual problems that limit consent validity or protocol compliance; able to cooperate and understand instructions.
- No difficulty swallowing tablets, capsules, or gelcaps.
You will not qualify if you...
- Known allergy or intolerance to fish or fish oil compounds.
- Use of omega-3 supplements within 30 days before study start.
- Pregnant or breastfeeding women.
- Dependence on drugs of abuse or alcohol exceeding 3 units per day.
- Currently participating in another clinical trial receiving investigational treatment.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Institut de recherche clinique du littoral (IRCL)
Maria, Quebec, Canada, G0C 1Y0
Actively Recruiting
2
Institut de recherche clinique du littoral (IRCL)
Rimouski, Quebec, Canada, G0K 1P0
Actively Recruiting
Research Team
S
Samuel Fortin, Investigator, Ph.D
CONTACT
A
Anne-Julie Landry, Clinical Project Manager, M.Sc, DESS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here